Publisher： Informa Healthcare
ISSN： 1354-3776
Source： Expert Opinion on Therapeutic Patents, Vol.10, Iss.3, 2000-03, pp. : 357-359
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Novel dialkoxypyrid-2-ylalkyl-1,3-dihydro-2H-imidazol-2-one derivatives are claimed for the treatment of atopic and asthmatic diseases. The claimed compounds are selective PDE4 inhibitors that are shown to inhibit PDE4B and are indicated to be useful in the treatment of dermatological diseases such as psoriasis and atopic dermatitis.
Related content
Novel 4-aminopyrazolo[3,4-b]pyridine PDE4 inhibitors
Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 1, 2005-01 ,pp. :
Access to resources
Recommend
By Norman P.
Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 7, 1998-07 ,pp. :
By Norman P.
Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 8, 1999-08 ,pp. :
The therapeutic potential of PDE4 inhibitors
Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. :
PDE4 inhibitors and chronic obstructive pulmonary disease
By Wolda S.L.
Expert Opinion on Emerging Drugs, Vol. 5, Iss. 3, 2000-10 ,pp. :